Analysts See $2.13 EPS for Gilead Sciences, Inc. (GILD)

Henrietta Strickland
July 15, 2017

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, May 2nd. The Sei Investments Company holds 21,609 shares with $1.07 million value, down from 30,622 last quarter. On average, equities analysts anticipate that Gilead Sciences, Inc. will post $8.37 EPS for the current fiscal year. Loomis Sayles Limited Partnership owns 1,290 shares. Gilead Sciences's dividend payout ratio (DPR) is now 21.99%. It has underperformed by 38.50% the S&P500.

Comerica Incorporated (NYSE:CMA) had an increase of 0.43% in short interest. 473.22 million shares or 6.83% less from 507.90 million shares in 2016Q3 were reported. First Manhattan stated it has 4,668 shares. Shares saw a steep increase in trading volume of 6.47% over the normal average daily volume. It has underperformed by 9.03% the S&P500.

Investors sentiment decreased to 0.7 in Q4 2016. Its down 0.23, from 0.93 in 2016Q3.

Gilead Sciences, Inc. (NASDAQ:GILD) stock soared 1.12% to $70.58 on the closing of 07/13/2017.

Several other hedge funds have also made changes to their positions in GILD. The biopharmaceutical company reported $2.20 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.18 by $0.02. Truepoint Inc holds 0.39% or 129,609 shares in its portfolio.

Hudson Valley Investment Advisors Inc decreased Gilead Sciences Inc (GILD) stake by 54.18% reported in 2016Q4 SEC filing. GILD's SI was 11.80M shares in July as released by FINRA. The company has market cap of $89.44 million. Buckingham Capital Mgmt invested in 18,259 shares. Moody Bank & Trust Tru Division holds 12,598 shares or 0.04% of its portfolio. Jefferies Group LLC restated a "buy" rating and issued a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, April 6th. (NASDAQ:GILD). Airain Limited owns 291,273 shares. Millennium Mngmt Ltd Liability Corporation accumulated 1.42 million shares. Lingohr & Partner Asset Gmbh reported 17,887 shares.

About Gilead Sciences Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need.

Since February 1, 2017, it had 0 insider buys, and 10 sales for $28.29 million activity. The stock of Gilead Sciences, Inc. WILSON GAYLE E sold 20,365 shares worth $1.41M. (NASDAQ:GILD) shares with value of $668,667 were sold by Cogan John Francis.

In related news, EVP Gregg H. Alton sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, July 3rd.

(NASDAQ:GILD). 17,882 are held by Kidder Stephen W. Sun Life Fin holds 0% of its portfolio in Gilead Sciences, Inc. Therefore 66% are positive.

On November 8, 2016 Mizuho added GILD to its research portfolio with an initial rating of "Buy". As per Wednesday, July 29, the company rating was maintained by RBC Capital Markets. Standpoint Research initiated the stock with "Buy" rating in Wednesday, February 3 report. Berenberg has "Buy" rating and $112 target. The ex-dividend date was Wednesday, June 14th. Commerzbank Aktiengesellschaft FI's holdings in Gilead Sciences were worth $35,847,000 at the end of the most recent quarter. (NASDAQ:GILD) rating on Wednesday, August 31. Citigroup has "Buy" rating and $105 target. The firm earned "Outperform" rating on Wednesday, November 2 by BMO Capital Markets. The stock has "Neutral" rating by Goldman Sachs on Thursday, March 23.

GILD has been the subject of several research reports. The biopharmaceutical company reported $2.20 EPS for the quarter, beating analysts' consensus estimates of $2.18 by $0.02. GILD's profit will be $2.81B for 8.28 P/E if the $2.13 EPS becomes a reality. (NASDAQ:GILD) by 37.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). Parnassus Investments sold 70,130 shares as Insperity Inc. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company's stock worth $358,000 after buying an additional 154 shares during the period. Itau Unibanco Ho (NYSE:ITUB) was raised too.

Investors sentiment decreased to 2.21 in 2016 Q4. Its down 1.19, from 2.38 in 2016Q3. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company's stock worth $100,000 after buying an additional 250 shares during the period. 134 funds opened positions while 102 raised stakes. The Texas-based Rench Wealth Management Inc. has invested 2.84% in the stock. Deprince Race Zollo invested 1.4% of its portfolio in Diebold Nixdorf Inc (NYSE:DBD). Parkside Bankshares And Tru reported 0% in Coty Inc (NYSE:COTY). Td Asset Mngmt invested in 0.12% or 1.00M shares. Private Bancorp Trust Co invested 0.09% of its portfolio in Comerica Incorporated (NYSE:CMA). Nomura Asset reported 0.03% in Comerica Incorporated (NYSE:CMA). Lowe Brockenbrough & holds 19,395 shares or 0.23% of its portfolio. Thrivent Financial For Lutherans, a Minnesota-based fund reported 12,870 shares. Alpine Woods Investors Ltd Llc reported 31,600 shares or 0.13% of all its holdings. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company's stock. Therefore 33% are positive. Novartis Ag had 26 analyst reports since July 28, 2015 according to SRatingsIntel. (NASDAQ:GILD) earned "Overweight" rating by Piper Jaffray on Friday, July 24. The firm has "In-Line" rating given on Wednesday, September 16 by Imperial Capital. Roth Capital maintained Insperity Inc (NYSE:NSP) on Tuesday, May 3 with "Buy" rating. The company was maintained on Wednesday, April 19 by Feltl Co. The stock of Wheaton Precious Metals Corp (NYSE:WPM) has "Neutral" rating given on Monday, August 15 by JP Morgan. Credit Suisse maintained Gilead Sciences, Inc. Oppenheimer has "Outperform" rating and $120 target. The company was maintained on Thursday, February 4 by Wedbush.

Since April 3, 2017, it had 13 buys, and 1 sale for $29,430 activity. DOYLE DAVID ROY also sold $318,953 worth of Brinker International, Inc.

Diebold Nixdorf, Incorporated provides connected commerce services, software and technology. The company has a market cap of $92.22 billion, a price-to-earnings ratio of 7.46 and a beta of 1.21. It now has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Other reports by Click Lancashire

Discuss This Article